The complexity of targeting EGFR signalling in cancer: from expression to turnover

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Epidermal growth factor receptor (EGFR) is frequently altered in human cancers.
• EGFR-targeted therapies, including antibodies and kinase inhibitors, are approved or in clinical trials.
• Predicting patient response to EGFR-targeted agents remains a significant clinical challenge.

Purpose of the Study:

• To review the fundamental signal transduction pathways mediated by activated EGFR.
• To emphasize the importance of understanding intracellular processes affecting EGFR sensitivity.
• To highlight the need for co-targeting additional proteins in EGFR-targeted cancer therapy.

Main Methods:

• Review of established EGFR-mediated signaling pathways.
• Focus on intracellular protein-protein interactions, ubiquitination, endocytosis, and degradation of EGFR.
• Analysis of membrane-bound and endosomal EGFR signaling.

Main Results:

• EGFR signaling pathways are well-characterized but intracellular dynamics influencing sensitivity are less understood.
• Protein-protein interactions, ubiquitination, and endocytosis/degradation are emerging areas critical for EGFR sensitivity.
• Co-targeting upstream or downstream proteins alongside EGFR may enhance therapeutic outcomes.

Conclusions:

• A deeper understanding of EGFR intracellular trafficking and degradation is crucial for predicting treatment response.
• Targeting additional proteins interacting with EGFR is a promising strategy to overcome resistance and improve cancer therapy.
• Future research should focus on the interplay of EGFR signaling with cellular processes like ubiquitination and endocytosis.